mutant calreticulin peptide vaccine (Icahn School of Medicine)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namemutant calreticulin peptide vaccine (Icahn School of Medicine)
Drug Alias NamePeptide-based vaccine (Icahn school of medicine/)
ClassificationBiologics > Protein drugs > Recombinant polypeptideVaccines > Application > Therapeutic vaccine
Mechanisms of ActionCalreticulin modulators
TargetsCalreticulin
Therapy Area/IndicationsPrimary MyelofibrosisMyeloproliferative DisordersThrombocytosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIcahn School Of Medicine At Mount Sinai
China Registration ClassN/A

Develop Information

Active CompaniesIcahn School Of Medicine At Mount Sinai
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisMyeloproliferative DisordersThrombocytosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A